A 2-years post-doctoral position funded by INCa (Institut National du Cancer) is available at MEDyC research unit in Reims (France) – UMR CNRS 7369, “Extracellular matrix, Cancer and Therapeutic target” team.
This INCa-funded project is based on a unique academic-industry R&D partnership gathering together MEDyC unit (CNRS UMR7369), Gustave Roussy Institute and Apmonia Therapeutics, a biotech company dedicated to developing anti-cancer immunotherapy strategies.
The goal of the project is to deeply investigate the relevance of targeting the TSP-1/CD47 axis in the purpose of restoring anti-tumor immunity in ovarian cancer, one of the highest unmet medical needs in oncology. We will seek to open new therapeutic perspectives for the treatment of ovarian cancer focusing our attention on an optimized drug candidate (TAX2) with highly advanced preclinical characterization.
The team is therefore looking for a highly motivated candidate with significant background in oncoimmunology (knowledge and technical skills) and mouse tumor models (animal experimentation degree is an essential prerequisite).
Ideally, the candidate would have several years of research in the field of tumor microenvironment with expertise on extracellular matrix components.
Download the add for more information
Interested candidates are invited to send a detailed CV with publication list, motivation letter and referees names to Pr. Stéphane Dedieu ()